EGFR and non-small cell lung carcinoma: Although previous studies had reported several resistance mechanisms of EGFR TKIs for EGFR-mutant NSCLC patients, in many cases, the mechanisms remain unclear (Costa et al., 2014; Beau-Faller et al., 2014; Ogino et al., 2007; Engelman et al., 2007).